Equities research analysts expect Seattle Genetics, Inc. (NASDAQ:SGEN) to report $117.28 million in sales for the current quarter, according to Zacks. Six analysts have issued estimates for Seattle Genetics’ earnings. The lowest sales estimate is $112.00 million and the highest is $123.39 million. Seattle Genetics posted sales of $109.13 million during the same quarter last year, which would indicate a positive year over year growth rate of 7.5%. The business is expected to announce its next earnings results on Thursday, April 26th.

According to Zacks, analysts expect that Seattle Genetics will report full year sales of $117.28 million for the current year, with estimates ranging from $495.42 million to $566.10 million. For the next fiscal year, analysts expect that the firm will post sales of $726.76 million per share, with estimates ranging from $648.40 million to $833.66 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Seattle Genetics.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.02. The business had revenue of $129.61 million for the quarter, compared to analyst estimates of $123.99 million. Seattle Genetics had a negative net margin of 26.03% and a negative return on equity of 33.36%. The company’s quarterly revenue was up 23.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.39) earnings per share.

Several analysts have recently commented on SGEN shares. Zacks Investment Research lowered shares of Seattle Genetics from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. Barclays increased their price target on shares of Seattle Genetics from $55.00 to $60.00 and gave the company an “equal weight” rating in a research report on Monday, October 16th. Guggenheim reiterated a “buy” rating and issued a $72.00 price target on shares of Seattle Genetics in a research report on Monday, October 23rd. Jefferies Group reiterated a “buy” rating and issued a $53.00 price target on shares of Seattle Genetics in a research report on Thursday, October 26th. Finally, Bank of America upgraded shares of Seattle Genetics from an “underperform” rating to a “neutral” rating in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $64.56.

Seattle Genetics (NASDAQ SGEN) traded down $0.40 during mid-day trading on Monday, hitting $50.14. 2,640,000 shares of the stock traded hands, compared to its average volume of 1,330,000. The firm has a market capitalization of $7,160.00, a price-to-earnings ratio of -56.34 and a beta of 2.08. Seattle Genetics has a twelve month low of $45.31 and a twelve month high of $71.32.

In related news, COO Eric Dobmeier sold 35,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $58.25, for a total transaction of $2,038,750.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bros. Advisors Lp Baker bought 3,846,153 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were purchased at an average price of $52.00 per share, for a total transaction of $199,999,956.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 98,993 shares of company stock worth $5,603,714. 34.70% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. American International Group Inc. acquired a new position in shares of Seattle Genetics in the 4th quarter valued at $121,000. Quantbot Technologies LP boosted its holdings in shares of Seattle Genetics by 116.5% in the 3rd quarter. Quantbot Technologies LP now owns 2,654 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 1,428 shares during the last quarter. Bristlecone Advisors LLC acquired a new position in shares of Seattle Genetics in the 3rd quarter valued at $180,000. Virtu Financial LLC acquired a new position in shares of Seattle Genetics in the 3rd quarter valued at $203,000. Finally, Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Seattle Genetics in the 3rd quarter valued at $208,000. Institutional investors own 98.92% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/02/10/analysts-expect-seattle-genetics-inc-sgen-will-post-quarterly-sales-of-117-28-million.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Get a free copy of the Zacks research report on Seattle Genetics (SGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.